

such deficiency or credit the surplusage to Deposit Account 08-3255 and advise Applicant's Agent.

IN THE CLAIMS

✓
Please amend the claims as follows:

~~106~~ (Amended) The method of Claim [101, 102,] 103[, 104, or 105] wherein the form of hyaluronic acid comprises at least about 1.5mg/kg of patient body weight to whom the form of hyaluronic acid is administered.

~~107~~ (Amended) The method of Claim [101, 102,] 103[, 104, or 105] wherein the form of hyaluronic acid comprises at least two dosages, a priming dosage amount and an additional dosage amount and said form of hyaluronic acid is sodium hyaluronate.

~~108~~ (Amended) The method of Claim [101, 102,] 103[, 104 or 105] wherein the form of hyaluronic acid is at least about 12 mg/kg of patient body weight and said form of hyaluronic acid is sodium hyaluronate.

~~114~~ (Amended) The method of Claim 111[, 112 or 113] wherein the form of hyaluronic acid comprising hyaluronic acid and pharmaceutically acceptable salts thereof is at least about 6 mg/kg of patient body weight to whom the form of hyaluronic acid is administered.

Q2
cond
115 (Amended) The method of Claim 111[112 or 113] wherein the form of hyaluronic acid comprises at least two dosages, a priming dosage amount and an additional dosage amount.

Q3
131 (Amended) The method of Claim 130 wherein the administration [administration] is to modulate symptoms of allergy or asthma.

Q4
133 (Amended) The method of Claim 124, 125, 126, [127, 128, 129,] 130, 131 or 132 wherein the form of hyaluronic acid is sodium hyaluronate.

Q4
139 (Amended) A method of using ex-vivo hyaluronan perfusion to mobilize hematopoietic and dendritic-type [dendritic-type] cells out of an ex-vivo organ that has already been harvested from the donor by the infusion of an effective amount of hyaluronan to a patient wherein the form of hyaluronan is selected from hyaluronan and pharmaceutically acceptable salts thereof having a molecular weight less than 750,000 daltons.

Q5
143 (Amended) The method of Claim [137,] 138, 139[140,] or 141[94 or 142] wherein the form of hyaluronic acid is sodium hyaluronate.

REMARKS

The Examiner has requested that Applicant elect a single invention to which the claims must be restricted. Applicant hereby elects the invention of Group IV; namely Claims 103, 106-111, 114-124, 130-131, 133, 136, 138-139, 141 and 143-144; Group VII, namely Claims 125-126 and 133-136; and Group X, namely